CTP 518

Drug Profile

CTP 518

Alternative Names: CTP-518; Deuterium-modified atazanavir

Latest Information Update: 26 Jun 2013

Price : $50

At a glance

  • Originator Concert Pharmaceuticals
  • Class Antiretrovirals; Isotopes; Oligopeptides; Organic deuterium compounds; Pyridines; Small molecules
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 26 Jun 2013 Discontinued - Phase-I for HIV infections in USA prior to 26 June 2013 (PO)
  • 11 Nov 2009 Phase-I clinical trials in HIV infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top